The Latest

• 

  Nobel Prize victory spotlights immunology’s value in pharma

  While saturated with mature blockbusters, the immunology space is vibrating with new potential breadwinners from the top companies.

  Biotech

• 

  Vertex’s quest for a breakthrough in Type 1 diabetes

  The race is on for an insulin-producing treatment that doesn’t require immune suppressing drugs.

  Biotech

• 

  Dr. Peter Marks, former top FDA vaccine official, joins Eli Lilly

  Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work at the big Indianapolis drugmaker.

  Pharma

• 

  As setbacks plague other companies, MindMed becomes a front-runner in the psychedelics race

  Challenges faced by other drugmakers have reinforced, rather than discouraged, MindMed’s approach to psychedelic drug R&D for anxiety and other disorders.

  Biotech

• 

  Q&A

  Overcoming past mistakes, generics powerhouse Teva embraces an innovative ‘mindset change’

  In the three years since a leadership change, Teva has evolved its R&D approach beyond a long history making copycat medicines.

  Leadership

• 

  Trump administration could lower drug prices by making other nations pay more

  The Trump administration often touts its efforts to lower prices in the U.S. by matching what other countries pay, but there’s more to this policy story.

  Pharma

• 

  With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs?

  The only woman to head up a company in Big Pharma is stepping down from the role at the end of the year.

  Leadership

• 

  Takeda, in reversal, abandons cell therapy research

  The Japanese pharmaceutical company, which had made cell therapy a priority a few years ago, aims to partner its work while prioritizing investments elsewhere.

  Pharma

• 

  Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?

  This week’s launch of subcutaneously administered Keytruda Qlex gives Merck a safety net for the cancer drug’s daunting patent cliff.

  Commercialization

• 

  AstraZeneca’s at-home flu vaccine is a breakthrough that could pave the way for others

  FluMist Home could be a test case for at-home vaccines against a backdrop of challenging regulatory shifts.

  Biotech

• 

  Top pharma industry conferences in 2026

  Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in 2026.

  Biotech

• 

  Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain?

  The new treatment may only offer modest benefits, but could gain traction in a market with few other options.

  Biotech

• 

  As obesity M&A heats up, pharmas could get ‘blinded by opportunity’

  With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.

  Biotech

• 

  Is pharma’s IRA pricing battle running out of steam?

  Despite recent court losses, the legal tides could still turn in the industry’s favor.

  Commercialization

• 

  Why Xoma, a drug royalty firm, is hunting biotech ‘zombies’

  The collapse in value of many biotechs over the past few years has created an opportunity for specialists like Xoma to “do the right thing” for the ecosystem and liquidate them, its executives say.

  Biotech

• 

  Can a multibillion-dollar deal put Pfizer in the obesity big leagues?

  After a couple failed attempts on its own, Pfizer is hitting the M&A gas to bring in candidates that could help it become a weight loss heavyweight.

  Biotech

• 

  Pharma’s next generation of blockbuster antibodies takes a ‘more is better’ approach

  Why multi-specific antibodies are seeing a fresh surge of industry buzz.

  Biotech

• 

  Q&A

  Lilly’s Alzheimer’s efforts depend on newer, better biomarkers and diagnostics

  The pharma giant’s R&D in Alzheimer’s didn’t end with last year’s Kisunla approval, and diagnostics could define where the company goes next.

  Biotech

• 

  With DTC ads under fire, pharma companies need to pivot

  An executive order from HHS doesn’t prohibit direct outreach to consumers, but drugmakers will need to rethink their outreach strategies.

  Pharma

• 

  3 FDA approval firsts that could be around the corner

  Several market-altering decisions are on the agency’s docket for the rest of 2025.

  Biotech

• 

  How pharma can play a role in the $1 trillion healthcare reinvention

  A report from PwC takes a long-term approach to the shifts in healthcare and finds that efficiency in R&D and adaptable business models will define the drugmaker of the future.

  Pharma

• 

  AI agents are coming to pharma. Here’s what it means for clinical trials.

  The high-tech helpers could autonomously navigate tedious tasks — but have to be carefully implemented.

  Pharma

• 

  Biotech’s VC slowdown forces young drugmakers to adapt in the ‘valley of death’

  Amid the sector’s long winter, startups are shifting gears to extend their cash runways.

  Biotech

• 

  From atop Mt. Fuji, a Takeda team heralds a need for human plasma

  The climb aimed to raise money and awareness as Takeda ramps up its plasma-derived therapy presence in Japan.

  Patient

• 

  Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics?

  While mRNA changed the game in vaccines, leveraging the technology to develop treatments has been trickier to navigate.

  Biotech